You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

Mavorixafor - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for mavorixafor and what is the scope of patent protection?

Mavorixafor is the generic ingredient in one branded drug marketed by X4 Pharms and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mavorixafor has forty-seven patent family members in eighteen countries.

One supplier is listed for this compound.

Summary for mavorixafor
International Patents:47
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 5
Patent Applications: 517
What excipients (inactive ingredients) are in mavorixafor?mavorixafor excipients list
DailyMed Link:mavorixafor at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for mavorixafor
Generic Entry Date for mavorixafor*:
Constraining patent/regulatory exclusivity:
TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS)
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for mavorixafor

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
X4 PharmaceuticalsPhase 1
X4 PharmaceuticalsPhase 3
X4 PharmaceuticalsPhase 2

See all mavorixafor clinical trials

US Patents and Regulatory Information for mavorixafor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
X4 Pharms XOLREMDI mavorixafor CAPSULE;ORAL 218709-001 Apr 26, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
X4 Pharms XOLREMDI mavorixafor CAPSULE;ORAL 218709-001 Apr 26, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
X4 Pharms XOLREMDI mavorixafor CAPSULE;ORAL 218709-001 Apr 26, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.